ALXO
ALX Oncology Holdings Inc.
Biotechnology · Healthcare · United States
1.22
close · 2026-10-30
value
5
cheaper than peers5
quality
35
stronger fundamentals35
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.24× | 70 |
| cash flow yield, latest year | -50.0% | 26 |
| cash flow yield, 3 years ago | -53.7% | 19 |
| cash flow yield, 1 year ago | -72.5% | 18 |
| cash flow yield, 2 years ago | -78.0% | 16 |
| earnings yield, 3 years ago | -248.4% | 15 |
| earnings yield, 2 years ago | -306.6% | 11 |
| earnings yield, latest year | -155.7% | 10 |
| earnings yield, 1 year ago | -211.5% | 10 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| debt to equity | 8.1% | 42 |
| return on equity | -80.6% | 37 |
3 of 4 measures available
Facts
| market cap | $169M |
| free cash flow | -$41.2M |
| employees | 48 |
| first trade | 2020-07-17 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-13 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.90 | -2.58 | -3.74 | -3.03 |
| free cash flow | -$84.4M | -$122.4M | -$131.6M | -$90.7M |
| net income | -$101.7M | -$134.8M | -$160.8M | -$123.5M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | -$3.2M | $0 | $0 | $0 |